NFATC1 and metabolic dysfunction-associated steatotic liver disease: For instance, TUDCA can pharmacologically inhibit endoplasmic reticulum (ER) stress responses, overcoming NFATc1 activation and halting the progression from nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) [3].